89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

March 27, 2024

https://www.globenewswire.com/news-release/2024/03/27/2853082/0/en/89bio-Receives-EMA-PRIME-Status-for-Pegozafermin-in-the-Treatment-of-Metabolic-Dysfunction-Associated-Steatohepatitis-MASH-with-Fibrosis-and-Compensated-Cirrhosis.html

–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin–

–Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis in MASH patients with compensated cirrhosis (F4) is planned to initiate in the second quarter of 2024–

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.